NeoGraph Analytics
BiotechnologyNorth America2023 – 2032

Global Europe CRISPR Technology Market Size, Share and Trends Analysis

Europe CRISPR Technology Market valued at USD 0.85B in 2023, projected to reach USD 3.11B by 2032 at 15.5% CAGR.

Revenue, 2023

$0.8B

Forecast, 2032

$3.1B

CAGR, 2024-2032

15.5%

Report Coverage

North America

Code: europe-crispr-technology-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The European CRISPR technology market was valued at approximately USD 0.85 billion in 2023 and is projected to reach USD 3.11 billion by 2032, growing at a 15.5% CAGR. Key growth drivers include rising R&D investments in gene therapies, supportive EU regulatory frameworks, and expanding clinical trials. Germany, the UK, and France lead regional adoption. CRISPR Therapeutics AG is the dominant European player, with increasing competition from Editas Medicine and Intellia Therapeutics.

02

Key Highlights

1

Europe CRISPR market projected to reach USD 3.11B by 2032 at 15.5% CAGR from USD 0.85B in 2023.

2

CRISPR kits and reagents dominate with 45% market share; therapeutics segment grows fastest.

3

Germany leads European adoption driven by robust biotech infrastructure and R&D funding.

03

Market Overview

Market Context

Europe represents a significant share of the global CRISPR technology market, supported by strong academic research institutions, favorable funding mechanisms, and an evolving regulatory environment. Germany, the UK, and France serve as primary growth engines. The market spans therapeutics, agricultural biotechnology, and industrial applications, with clinical therapeutics emerging as the fastest-growing segment driven by CASGEVY approval.

Europe holds approximately 30% of the global CRISPR technology market, driven by strong biotech ecosystems in Germany, the UK, and France. The market is experiencing rapid growth due to expanding therapeutic pipelines and increasing adoption of CRISPR tools in drug discovery and agricultural biotechnology.

Market Stage

High growth

Adoption Level

Growing

Key Trends

Growing in vivo gene editing clinical trials across EU member statesIncreasing CRISPR adoption in agricultural biotechnology and food securityRising partnerships between European pharma and CRISPR therapeutics developersExpansion of CRISPR-based diagnostics post-pandemic demand
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 15.5%

Base Year (2023)

$0.8B

Forecast (2032)

$3.1B

CAGR (2024-2032)

15.5%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$0.85B
2024$0.98B
2025$1.13B
2026$1.31B
2027$1.51B
2028$1.75B
2029$2.02B
2030$2.33B
2031$2.69B
2032$3.11B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

The European CRISPR market is forecast to grow from USD 0.85B to USD 3.11B by 2032 at a 15.5% CAGR. Growth is primarily driven by expanding clinical trials, increasing therapeutic approvals, and rising agricultural biotech applications. In vivo gene editing and base editing technologies represent the highest future revenue potential.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America40.0%16.2%United States
Europe30.0%15.5%Germany
Asia Pacific30.0%18.3%China

North America

#1
Share: 40.0%CAGR: 16.2%

Largest market: United States

Europe

#2
Share: 30.0%CAGR: 15.5%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Rising prevalence of genetic disorders driving therapeutic demand
  • Increased EU funding for gene-editing research initiatives
  • Expanding CRISPR applications beyond therapeutics into agriculture
06

Market Segmentation

By Application
Market share distribution across 4 segments
By Application — market share by segment, in percent.
SegmentShare
Drug Discovery & DevelopmentLargest application segment supported by European pharma R&D investments.35.0%
Clinical TherapeuticsGrowing segment driven by approved CRISPR therapies and pipeline expansion.30.0%
Agriculture & FoodIncreasing gene-edited crop development under EU regulatory evolution.20.0%
Industrial BiotechnologyBiofuel and enzyme engineering applications gaining commercial traction.15.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
By Product Type
Market share distribution across 3 segments
By Product Type — market share by segment, in percent.
SegmentShare
CRISPR Kits & ReagentsDominant segment driven by widespread research and diagnostic applications across European labs.45.0%
CRISPR TherapeuticsFastest-growing segment fueled by CASGEVY approval and expanding clinical pipelines.30.0%
CRISPR ServicesCustom gene-editing services for pharma and biotech companies gaining traction.25.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)
07

Regional Analysis

1

North America

Lead: United States
CAGR: 16.2%Share: 40.0%

Largest market driven by FDA approvals, extensive clinical trials, and major company headquarters.

2

Europe

Lead: Germany
CAGR: 15.5%Share: 30.0%

Second-largest market with strong biotech hubs in Germany, UK, and France; EU regulatory frameworks shaping growth.

3

Asia Pacific

Lead: China
CAGR: 18.3%Share: 30.0%

Fastest-growing region driven by government investments in gene editing and expanding biotech infrastructure.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
United States
38.0%
+16.0%
Germany
18.0%
+15.8%
China
15.0%
+19.0%
08

Competitive Landscape

C

CRISPR Therapeutics AG

Switzerland

Leader350M

Pioneer of approved CRISPR therapy CASGEVY; strong oncology and hemoglobinopathy pipeline across European clinical sites.

Swiss-US biotech leader pioneering CRISPR-based therapies with the first approved CRISPR therapy CASGEVY for sickle cell disease and beta-thalassemia.

E

Editas Medicine

United States

Challenger120M

Clinical-stage company advancing in vivo and ex vivo editing with Cas12a platform; BRILLIANCE trial showed 79% vision improvement in LCA10 patients.

Clinical-stage gene editing company leveraging CRISPR Cas12a and Cas9 systems to develop transformative genomic medicines for serious diseases.

I

Intellia Therapeutics

United States

Follower180M

Leading in vivo gene editing with nexiguran ziclumeran for ATTR amyloidosis; Phase 3 MAGNITUDE-2 trial underway with European sites.

Leading in vivo CRISPR therapeutics developer advancing liver-targeted and oncology gene-editing programs with proprietary LNP delivery technology.

09

Recent Developments

25
2025CRISPR Therapeutics

Expanded CASGEVY commercial launch across 12 EU member states with new manufacturing partnerships

24
2024Intellia Therapeutics

Initiated Phase 3 MAGNITUDE-2 trial for nexiguran ziclumeran at European clinical sites

24
2024Merck KGaA

Acquired Mirus Bio to strengthen CRISPR delivery technology portfolio in Europe

10

Regulatory Landscape

EU Gene Therapy Medicinal Products Directive (2001/83/EC) governing CRISPR therapeutic approvalsEuropean Court of Justice 2018 ruling on gene-edited organisms under EU GMO DirectiveEMA Advanced Therapy Medicinal Products (ATMP) framework for CRISPR-based therapiesEU Clinical Trials Regulation (EU) No 536/2014 governing CRISPR clinical trial applications
11

Research Methodology

Primary research

  • Expert interviews with European biotech executives
  • Surveys of clinical researchers and biotech firms

Secondary research

  • Industry analyst reports
  • Company financial filings
  • EU regulatory databases
  • Clinical trial registries

Validation: Triangulation method cross-referencing primary interviews, secondary sources, and regulatory filings

12

Strategic Takeaways

Investors

Europe's CRISPR market offers strong growth potential with 15.5% CAGR; prioritize companies with EU clinical trial approvals.

Operators

Expand CRISPR service offerings in Germany and UK to capture growing demand from pharma and academic clients.

Policymakers

Evolving EU GMO regulations will significantly impact agricultural CRISPR adoption timelines.

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.